Autres langues Mendus AB

Actions

IMMU

SE0022239950

Recherche biotechnologique et médicale

Temps Différé Nasdaq Stockholm 18:00:00 10/09/2026			Varia. 5j.	Varia. 1 janv.
6,950 ^SEK	-5,44%		-5,57%	+24,11%

20/08	Transcript : Mendus AB, Q2 2026 Earnings Call, Aug 20, 2026
20/08	Mendus AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

24/08	Mendus (Q2 Review): Important CML Readout Near
20/08	Mendus AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
20/08	MENDUS AB INTERIM REPORT APRIL– JUNE 2026
13/08	Invitation to presentation of Mendus' second quarter 2026 financial report and business update
31/07	Change in number of shares and votes in Mendus AB (publ)
16/07	Mendus announces collaboration with the South Australian Health and Medical Research Institute (SAHMRI) to support preparation of the VITAL-TFR2 trial in chronic myeloid leukemia (CML)
16/07	Mendus AB and South Australian Health and Medical Research Institute Announce Collaboration to Support Preparation of the Vital-TFR2 Trial in Chronic Myeloid Leukemia
08/07	Mendus Completes First Stage Recruitment for Vididencel Trial
08/07	Mendus reports complete enrollment of the first stage of the VITAL-CML trial
08/07	Mendus AB Reports Complete Enrollment of the First Stage of the Vital-Cml Trial
23/06	Mendus AB (publ) has decided on directed issues of Class C shares and transfer of own ordinary shares
10/06	Mendus AB (publ) repurchases outstanding warrants from Fenja
02/06	Mendus reports long-term progression-free survival associated with broad immune activation in high-risk ovarian cancer
02/06	Mendus Reports Additional Positive Results from the Phase 1b Alison Trial in High-Grade Serous Ovarian Cancer
27/05	Mendus AB (publ) has resolved to transfer own shares
13/05	Mendus says vididencel combination potential confirmed
13/05	Preclinical data presented at CIMT confirm combination potential of vididencel with current and upcoming CML treatments
13/05	Mendus AB Presents Preclinical Data Confirming Combination Potential of Vididencel with Current and Upcoming Cml Treatments
11/05	Mendus (Q1 review): CML Phase I Initiated
08/05	Report from the Annual General Meeting of Mendus AB (publ) on 8 May 2026
08/05	Mendus AB Elects Sijmen De Vries as Board Member
08/05	Mendus AB Interim Report January – March 2026
08/05	Mendus AB Reports Earnings Results for the First Quarter Ended March 31, 2026
01/05	Invitation to presentation of Mendus' first quarter 2026 financial report and business update
21/04	Flerie’s portfolio company Mendus advances clinical program with first patient enrolled in phase 1b trial